A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (NCT05243550)

🧪 Interventions in This Study

• UGN-102 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (65 Sites)

Showing the first 25 of 65 sites.

• Arizona Urology Specialists — Tucson, Arizona
• Loma Linda University Medical Center — Loma Linda, California
• Genesis Research — San Diego, California
• Wichita Urology Group — Wichita, Kansas
• John Hopkins University — Baltimore, Maryland
• Chesapeake Urology Research Associates — Hanover, Maryland
• University of Missouri — Columbia, Missouri
• Atlantic Health System — Morristown, New Jersey
• Great Lakes Physician dba WNY Urology Associates — Cheektowaga, New York
• AccuMed Research Associates — Garden City, New York
• Manhattan Medical Research — New York, New York
• NYU Langone Health — New York, New York
• Mount Sinai — New York, New York
• Urology Associates, P.C. — Nashville, Tennessee
• Houston Methodist Research Institute — Houston, Texas
• Spokane Urology, P.S. — Spokane, Washington
• Medical University Vienna, Department of Urology — Vienna,
• Multiprofile Hospital for Active Treatment - Blagoevgrad — Blagoevgrad,
• Multiprofile Hospital for Active Treatment "Dr. Tota Venkova", Gabrovo, Department of Urology — Gabrovo,
• Multiprofile Hospital for Active Treatment "Sveti Nikolai Chudotvorets", Lom — Lom,
• Multiprofile Hospital for Active Treatment "City Clinic - Sveti Georgi" — Montana,
• University Multiprofile Hospital for Active Treatment "Dr. Georgi Stranski", Pleven, Urology Clinic — Pleven,
• University Multiprofile Hospital for Active Treatment "Sveta Marina" - Pleven, Department of Urology — Pleven,
• University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv — Plovdiv,
• University Multiprofile Hospital for Active Treatment, Plovdiv — Plovdiv,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Bladder Cancer

• Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer — St Louis, Missouri
• Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer — Calgary, Alberta
• Determinants of Bladder Cancer Recurrence Study (The DETER Study) — Basking Ridge, New Jersey
• Quality of Life in Patients With Bladder Cancer — New York, New York
• A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer — Hartford, Connecticut
• A Diagnostic for the Early Detection of Bladder Cancer — Long Beach, California

Explore by condition: All Bladder Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.